|Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy|
S Bowyer, P Prithviraj, P Lorigan, J Larkin, G McArthur, V Atkinson, ...
British journal of cancer 114 (10), 1084-1089, 2016
|Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases|
S Parakh, JJ Park, S Mendis, R Rai, W Xu, S Lo, M Drummond, C Rowe, ...
British journal of cancer 116 (12), 1558-1563, 2017
|Evolution of anti-HER2 therapies for cancer treatment|
S Parakh, HK Gan, AC Parslow, IJG Burvenich, AW Burgess, AM Scott
Cancer treatment reviews 59, 1-21, 2017
|Antibody–drug conjugates for cancer therapy|
AC Parslow, S Parakh, FT Lee, HK Gan, AM Scott
Biomedicines 4 (3), 14, 2016
|Late presentation of generalised bullous pemphigoid‐like reaction in a patient treated with pembrolizumab for metastatic melanoma|
S Parakh, R Nguyen, JM Opie, MC Andrews
Australasian Journal of Dermatology 58 (3), e109-e112, 2017
|Antibody-mediated delivery of therapeutics for cancer therapy|
S Parakh, AC Parslow, HK Gan, AM Scott
Expert opinion on drug delivery 13 (3), 401-419, 2016
|Outcomes of haematology/oncology patients admitted to intensive care unit at T he C anberra H ospital|
S Parakh, A Piggin, T Neeman, I Mitchell, P Crispin, A Davis
Internal medicine journal 44 (11), 1087-1094, 2014
|Autoantibodies may predict immune-related toxicity: results from a phase i study of intralesional bacillus calmette–guérin followed by ipilimumab in patients with advanced …|
J Da Gama Duarte, S Parakh, MC Andrews, K Woods, A Pasam, C Tutuka, ...
Frontiers in Immunology 9, 411, 2018
|Autoantibodies may predict immune-related toxicity: Results from a phase I study of intralesional Bacillus Calmette-Guérin followed by ipilimumab in patients with advanced …|
JDG Duarte, S Parakh, MC Andrews, K Woods, A Pasam, C Tutuka, ...
Front Immunol 9, 411, 2018
|Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti‐PD‐1 Therapy|
S Parakh, J Cebon, O Klein
The oncologist 23 (7), 849, 2018
|Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a|
IJG Burvenich, S Parakh, FT Lee, N Guo, Z Liu, HK Gan, A Rigopoulos, ...
Theranostics 8 (15), 4199, 2018
|Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia|
S Parakh, HL Wong, R Rai, S Ali, K Field, J Shapiro, R Wong, L Nott, ...
Journal of geriatric oncology 6 (5), 387-394, 2015
|Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.|
S Parakh, C Murphy, D Lau, JS Cebon, MC Andrews
Journal of clinical pharmacy and therapeutics 40 (1), 121-123, 2014
|Molecular imaging and quantitation of EphA2 expression in xenograft models with 89Zr-DS-8895a|
IJG Burvenich, S Parakh, HK Gan, FT Lee, N Guo, A Rigopoulos, ST Lee, ...
Journal of Nuclear Medicine 57 (6), 974-980, 2016
|Receptor occupancy imaging studies in oncology drug development|
IJG Burvenich, S Parakh, AC Parslow, ST Lee, HK Gan, AM Scott
The AAPS journal 20 (2), 1-16, 2018
|Regorafenib-induced hyperammonemic encephalopathy.|
JC Kuo, S Parakh, D Yip
Journal of clinical pharmacy and therapeutics 39 (4), 446-448, 2014
|Real‐world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma|
S Parakh, M Randhawa, B Nguyen, L Warburton, MA Hussain, J Cebon, ...
Asia‐Pacific Journal of Clinical Oncology 15 (1), 26-30, 2019
|Cholecystitis after yttrium-90 resin microsphere radioembolization treatment: clinical and pathologic findings|
S Parakh, S Gananadha, R Allen, D Yip
Asian journal of surgery 39 (3), 144-148, 2016
|Novel approaches to undergraduate oncology education|
FJ Ha, S Parakh
Journal of Cancer Education 33 (3), 500-504, 2018
|Current development of monoclonal antibodies in cancer therapy|
S Parakh, D King, HK Gan, AM Scott
Current Immunotherapeutic Strategies in Cancer, 1-70, 2020